Editorial stack guide · Fat loss
Fat loss: AOD-9604, the GLP-1 conversation, lifestyle
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · Fat loss stack
The fat-loss conversation crosses three distinct lanes in the UK. AOD-9604 is a research-tier peptide with paused Phase 2b development. Licensed GLP-1 medications (semaglutide, tirzepatide) sit in the Prescription-Only Medicine category accessed through GPhC pharmacies and GMC clinics. Lifestyle anchors (calorie balance, training, sleep, behavioural support) carry the largest evidence base and form the foundation that any pharmacological intervention is added to. PeptideClear publishes encyclopedia commentary only. We do not recommend specific stacks for specific people. A combination of peptides should be discussed with a UK-registered prescriber.
Compounds and approaches in the fat-loss conversation
Three distinct lanes appear when fat loss is discussed alongside peptide research. Each sits in a different regulatory category. Each carries a different evidence weight. They should not be treated as components of a single stack.
AOD-9604
Evidence: Mixed evidenceAOD-9604 is a synthetic fragment corresponding to residues 176 to 191 of human growth hormone. The compound was developed by Metabolic Pharmaceuticals in Australia under the hypothesis that the C-terminal fragment retains the lipolytic activity of full-length growth hormone without the broader signalling profile. Preclinical animal studies supported the lipolytic claim. Phase 2b human obesity trials did not produce results supporting continued development at the doses studied. Development was paused. The compound has subsequently been marketed as a research peptide.
Encyclopedia entry for AOD-9604 ·Licensed GLP-1 medications (editorial framing only)
Evidence: Human RCTSemaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) are licensed Prescription-Only Medicines in the UK. Tirzepatide additionally activates the GIP receptor in addition to the GLP-1 receptor. Both have extensive Phase 3 trial data (STEP trials for semaglutide, SURMOUNT trials for tirzepatide) reporting clinically meaningful weight reduction across 68-week to 72-week study periods. Access in the UK is through GPhC-regulated pharmacies and GMC-registered clinics after clinical assessment, with NHS pathway access subject to eligibility criteria.
UK GLP-1 clinic comparison ·Lifestyle anchors
Evidence: Human RCTThe largest and most replicated evidence base for sustained fat loss sits outside the peptide category entirely. NICE guidance for weight management in adults (NG189), SACN dietary reference values, and the British Dietetic Association evidence reviews converge on a small set of high-leverage anchors: sustained energy deficit through dietary pattern change, regular physical activity combining cardiorespiratory and resistance components, adequate sleep duration and quality, and structured behavioural support. These are the foundation that pharmacological interventions add to, not a replacement for.
What the literature shows
The AOD-9604 evidence trajectory is informative as a case study. Preclinical rodent studies from Metabolic Pharmaceuticals and academic collaborators in the late 1990s and early 2000s supported the lipolytic-without-growth-hormone-signalling hypothesis. Translation to human Phase 2b trials produced disappointing efficacy at the doses tested. Development for the obesity indication was paused. Subsequent appearance on the research peptide market reflects commercial availability rather than a positive clinical signal.
The GLP-1 evidence base is the strongest in modern obesity pharmacotherapy. The STEP programme established semaglutide 2.4 mg weekly for weight management with mean body weight reductions in the 15 to 17 percent range over 68 weeks. The SURMOUNT programme established tirzepatide with reductions reaching 20 percent or higher at the 15 mg weekly dose over 72 weeks. Cardiovascular outcome data from SELECT supports a separate cardiovascular indication for semaglutide. The clinical trial evidence base is substantial, replicated, and contributed to UK MHRA marketing authorisation and NICE technology appraisal recommendations.
The lifestyle literature has decades of evidence behind it. Behavioural weight management programmes meeting the NICE NG189 criteria typically achieve modest but clinically meaningful weight loss when delivered with adequate intensity and duration. The combination of structured dietary support, increased physical activity and behavioural change techniques produces durable results in a subset of participants. Outcomes are reliably improved when lifestyle support is paired with pharmacological treatment in patients who meet prescribing criteria.
What we do not know
- · Whether AOD-9604 produces clinically meaningful weight reduction at any human dose, given the negative Phase 2b signal.
- · Long-term safety and durability of the GLP-1 weight-management indication beyond the trial follow-up periods published to date.
- · Whether weight regain after GLP-1 discontinuation can be mitigated by post-treatment lifestyle pattern, and what the optimal transition protocol looks like.
- · Whether any research-tier peptide alters the trajectory of weight loss when added to a licensed GLP-1 medication in a controlled trial. None has been studied this way in published work.
- · The optimal lifestyle pattern to pair with GLP-1 treatment to preserve lean mass during accelerated weight loss.
- · Long-term safety of research-tier sources of semaglutide and tirzepatide (which sit outside the licensed supply chain) including purity, potency consistency and immunogenicity profile.
UK regulatory framing
AOD-9604
Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation as a medicine. Sold by a subset of UK research peptide retailers under research-use-only framing. Not stocked by UK pharmacies or clinics in any clinical context.
Semaglutide and tirzepatide
Both are MHRA-authorised Prescription-Only Medicines. Tirzepatide is marketed as Mounjaro for weight management and type 2 diabetes. Semaglutide is marketed as Wegovy (weight management) and Ozempic (type 2 diabetes). UK access requires clinical assessment by a registered prescriber and dispensing through a GPhC-regulated pharmacy. NHS access is subject to NICE eligibility criteria and ICB rollout. Private access is available through specialist clinics.
Research-tier sources of POM medications
A subset of research peptide retailers stocks compounds matching the active ingredient names of licensed GLP-1 medications. PeptideClear does not cover this route. Use a GPhC-regulated pharmacy with a GMC prescriber for licensed GLP-1 medications. Grey-market sources sit outside the licensed supply chain and outside the framework that pharmacovigilance, batch traceability and clinical oversight depend on.
How a UK practitioner would discuss this
A UK GP or weight-management specialist approaching this conversation will typically begin with baseline assessment: BMI, waist circumference, comorbidities, cardiovascular risk profile, mental health history, and where indicated screening for treatable secondary causes of weight gain. NICE NG189 sets the framework for adult weight management, with structured tier 2 and tier 3 services forming the lifestyle-led foundation. NICE TA875 (semaglutide) and TA1026 (tirzepatide) define the criteria under which GLP-1 medications are NHS-funded.
The conversation about licensed GLP-1 medications is increasingly standard in UK primary care and private weight management. A prescriber will discuss eligibility, expected weight trajectory, side-effect profile, monitoring requirements, and the discontinuation question. The lifestyle pattern that supports the medication is part of the same conversation, not a separate one. Research peptides do not feature in this clinical pathway.
A prescriber discussing AOD-9604 with a curious patient would frame it as a research compound with a paused development history, no UK marketing authorisation, no integration into licensed weight-management pathways, and no role to play alongside licensed GLP-1 medications under current evidence. The conversation typically routes back to the licensed pathway plus lifestyle anchors.
Where to learn more
- · Encyclopedia entry: AOD-9604
- · UK clinic comparison: Best UK GLP-1 clinics
- · UK clinic comparison: Best UK GLP-1 clinics for women
- · NHS pathway: NHS access to weight-management medications
- · Aftercare pillar: life after GLP-1 treatment
- · Protein pillar: GLP-1 and protein intake
- · Clinic directory: all UK weight-management clinics
- · Glossary: peptide and weight-management terminology
Frequently asked questions
Can I buy tirzepatide in the UK?
Is AOD-9604 a substitute for a GLP-1 medication?
What does the AOD-9604 literature actually show?
What are the lifestyle anchors that actually matter?
Where should I go to discuss medication options?
PeptideClear publishes encyclopedia commentary only. We do not recommend specific stacks for specific people. A combination of peptides should be discussed with a UK-registered prescriber. AOD-9604 is sold under research-use-only framing. Licensed GLP-1 medications are Prescription-Only Medicines accessed through GPhC-regulated pharmacies and GMC-registered clinics.
Read our full methodology and how we are funded.
Ready to buy
Shop UK peptides, collagen and GLP-1 routes
Compare UK retailers, clinics and pharmacies across every PeptideClear category.